Embecta Corp. (FRA:JX7)
| Market Cap | 156.11M -75.0% |
| Revenue (ttm) | 904.16M -3.4% |
| Net Income | 97.05M +111.9% |
| EPS | 1.63 +111.2% |
| Shares Out | n/a |
| PE Ratio | 1.61 |
| Forward PE | 2.13 |
| Dividend | 0.52 (20.05%) |
| Ex-Dividend Date | Feb 27, 2026 |
| Volume | n/a |
| Average Volume | 191 |
| Open | 2.586 |
| Previous Close | 2.437 |
| Day's Range | 2.578 - 2.591 |
| 52-Week Range | 2.437 - 12.900 |
| Beta | n/a |
| RSI | 17.03 |
| Earnings Date | May 5, 2026 |
About Embecta
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. [Read more]
Financial Performance
In fiscal year 2025, Embecta's revenue was $1.08 billion, a decrease of -3.80% compared to the previous year's $1.12 billion. Earnings were $95.40 million, an increase of 21.84%.
Financial numbers in USD Financial StatementsNews
Embecta price target lowered to $3 from $11 at BofA
BofA analyst Travis Steed lowered the firm’s price target on Embecta (EMBC) to $3 from $11 and keeps an Underperform rating on the shares. After having hosted 34 medtech companies…
Embecta Faces U.S. Reset as CEO Bets on GLP-1, Owen Mumford Diversification
Embecta NASDAQ: EMBC President and CEO Devdatt Kurdikar said the company's recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and inventory-relate...
embecta Completes Acquisition of Owen Mumford Holdings Limited
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has completed its previously announced...
Embecta Transcript: Bank of America Global Healthcare Conference 2026
U.S. instability from share loss and market softness prompted a guidance cut and accelerated diversification efforts. New products, B2B partnerships, and the Owen Mumford acquisition are expected to drive growth and broaden the portfolio. Free cash flow remains strong, supporting buybacks and debt reduction.
embecta to Participate at the 2026 BofA Securities Global Health Care Conference
PARSIPPANY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the 2026 BofA Securities Global Health Care Conference in Las ...
Embecta price target lowered to $5 from $12 at Mizuho
Mizuho lowered the firm’s price target on Embecta (EMBC) to $5 from $12 and keeps a Neutral rating on the shares.
Embecta Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Embecta Corp. (NASDAQ: EMBC). The investigation focuses on Embecta's execut...
Embecta Earnings Call Transcript: Q2 2026
Q2 2026 saw a 14.4% revenue decline year-over-year, driven by U.S. pen needle share loss and market softness, prompting a downward revision of full-year guidance. The Owen Mumford acquisition is set to diversify the portfolio and contribute $30 million to revenue.
Embecta Earnings release: Q2 2026
Embecta released its Q2 2026 earnings on May 5, 2026, summarizing the period's financial results.
Embecta Slides: Q2 2026
Embecta has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 5, 2026.
Embecta Quarterly report: Q2 2026
Embecta has published its Q2 2026 quarterly earnings report on May 5, 2026.
Embecta lowers FY26 adjusted EPS view to $1.55-$1.75 from $2.80-$3.00
Lowers FY26 revenue view to $1.015B-$1.035B from $1.071B-$1.093B. Consensus is for FY26 EPS $2.82 and for revenue $1.07B.
Embecta reports Q2 adjusted EPS 27c, consensus 42c
Reports Q2 revenue $22.18M, consensus $235.66M. “We were disappointed with our second quarter results as they were significantly below our expectations, driven by a combination of factors which impact...
embecta Announces Quarterly Cash Dividend
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.01 for each issued and outstanding sh...
Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical ...
Embecta management to meet virtually with BTIG
Virtual Meeting to be held on May 6 hosted by BTIG.
embecta to Report Fiscal Second Quarter Financial Results
PARSIPPANY, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medica...
Embecta price target lowered to $12 from $14 at Mizuho
Mizuho lowered the firm’s price target on Embecta (EMBC) to $12 from $14 and keeps a Neutral rating on the shares. The firm lowered estimates and price targets for several…
Embecta price target lowered to $22 from $25 at BTIG
BTIG lowered the firm’s price target on Embecta (EMBC) to $22 from $25 and keeps a Buy rating on the shares as part of a broader research name on Medical…
Embecta acquiring Owen Mumford Holdings
Embecta (EMBC) has entered into a definitive agreement to acquire Owen Mumford Holdings, a privately held, UK-based manufacturer of medical devices and drug-delivery technologies, in a transaction val...
embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited
Acquisition will position embecta to participate in the rapidly expanding market for drug-delivery devices supporting generic and branded therapies and accelerate transformation into a broad‑based med...
Embecta elects CEO Devdatt Kurdikar as chairman
Embecta (EMBC) announced that the board of directors of Embecta has elected Devdatt Kurdikar as chairman of the board and Claire Pomeroy as lead independent director, effective immediately. These chan...
embecta names new Chairman of the Board and Lead Independent Director
PARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical...
Embecta Earnings Call Transcript: Q1 2026
Q1 2026 revenue was $261M, down slightly year-over-year, with U.S. declines offset by strong international growth. Guidance for FY2026 is reaffirmed but expected near the lower end due to U.S. pricing headwinds, while international performance and GLP-1 opportunities remain strong.
Embecta Quarterly report: Q1 2026
Embecta has published its Q1 2026 quarterly earnings report on February 5, 2026.